Kamada announces first patient enrolled into trial of CYTOGAM

Kamada (KMDA) announced that the first patient was enrolled into an investigator-initiated post-marketing clinical trial of CYTOGAM, CMV-IGIV, to prevent late Cytomegalovirus, CMV, infection, a common post-transplant infectious complication that remains an unaddressed medical need, despite recent advances in anti-viral drug therapies. “Up to one third of kidney transplant patients may develop late CMV infection or disease after stopping initial anti-viral prophylaxis therapy,” said Amir London, Kamada’s Chief Executive Officer. “CYTOGAM is a critical life-saving therapeutic, and our support for this study further underscores Kamada’s commitment to serving the transplant community. We look forward to the results of this important post-marketing trial, led by two distinguished thought leaders in Drs. Kotton and Wojciechowski.”